EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients






Chemotherapy 40(2): 136-143

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients

We studied the impact of fluconazole prophylaxis (400 mg/day) on clinical features including fever and use of amphotericin in a randomized, double-blind, placebo-controlled (1:1 randomization) study among patients undergoing chemotherapy for leukemia and those undergoing bone marrow transplantation. Fluconazole or placebo was given throughout the period of neutropenia. Amphotericin was administered to 5 of 23 (22%) fluconazole recipients and 14 of 23 (58%) placebo recipients (p lt 0.01). Median duration of amphotericin used in fluconazole and placebo groups was 9 days (mean 10.8) and 13 days (mean 14) respectively. Patients who received fluconazole had significantly shorter duration of fever prior to treatment with amphotericin (days, median 5 vs. 9, p lt 0.05). Superficial fungal infections were noted in 8 (34%) fluconazole recipients and 19 (79%) placebo recipients (p = 0.002). Fluconazole was well tolerated. Prophylaxis with fluconazole resulted in a significant reduction in the empiric use of amphotericin, duration of fever and incidence of superficial fungal infections.

Accession: 002355876

DOI: 10.1159/000239184

Download PDF Full Text: Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients



Related references

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. ChemoTherapy 40(2): 136-143, 1994

Reduction in use of amphotericin amb with fluconazole f prophylaxis in neutropenic cancer patients pts. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 222, 1991

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clinical Infectious Diseases 28(2): 331-340, 1999

The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Journal of Antimicrobial Chemotherapy 33(2): 309-318, 1994

Oral fluconazole, rather than intravenous amphotericin B , as empiric antifungal treatment for neutropenic fever in breast cancer patients undergoing high dose chemotherapy and autologous hematopoietic stem cell transplant. Blood 88(10 SUPPL 1 PART 1-2): 265B, 1996

Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents. Mycoses 33 Suppl 1: 42-54, 1990

Fluconazole flu vs oral amphotericin b o amb for antifungal prophylaxis in neutropenic pts. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 215, 1992

The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. Journal of Antimicrobial ChemoTherapy 33(2): 309-318, 1994

Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews (): Cd000239-Cd000239, 2000

Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews (): Cd000239-Cd000239, 2015